Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251394
Status:
COMPLETED
Last Update Posted:
2010-01-29
First Post:
2005-11-08
Brief Title:
Study of Dynavaxs 1018 ISS Following Rituxan in Patients With B-Cell Follicular Lymphoma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
03-411
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Arnold Freedman MD
Old Organization:
Dana-Farber Cancer Institute
Collaborators
| Name | Class |
|---|---|
| Dynavax Technologies Corporation | INDUSTRY |
| James P Wilmot Cancer Center | OTHER |
| University of Rochester | OTHER |
| Brigham and Womens Hospital | OTHER |
| Massachusetts General Hospital | OTHER |